Zomedica Corp (ZOM)
$0.1302
Insights on Zomedica Corp
Increasing Revenue
Revenue is up for the last 5 quarters, 5.48M → 7.33M (in $), with an average increase of 6.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -491.0K → -22.40M (in $), with an average decrease of 2231.7% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 35.0% return, outperforming this stock by 66.6%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 147.6%
Performance
- $0.13$0.13$0.13
0.77%
Downside
Day's Volatility :2.79%
Upside
2.03%
- $0.12$0.25$0.13
7.69%
Downside
52 Weeks Volatility :51.02%
Upside
46.94%
Returns
| Period | Zomedica Corp | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.35% | 2.0% | 0.0% |
6 Months | -18.29% | 11.7% | 0.0% |
1 Year | -34.45% | 5.8% | 1.3% |
3 Years | -88.38% | 14.2% | -22.1% |
Highlights
Market Capitalization | 127.5M |
Book Value | $0.25 |
Earnings Per Share (EPS) | -0.03 |
Wall Street Target Price | 0.44 |
Profit Margin | -137.1% |
Operating Margin TTM | -155.23% |
Return On Assets TTM | -7.41% |
Return On Equity TTM | -13.61% |
Revenue TTM | 25.2M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 19.2% |
Gross Profit TTM | 13.7M |
EBITDA | -25.3M |
Diluted Eps TTM | -0.03 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.01 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 237.94%
Technicals Summary
Sell
Neutral
Buy
Zomedica Corp is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Zomedica Corp | -1.72% | -18.29% | -34.45% | -88.38% | -63.63% |
 Stryker Corporation | -4.59% | 29.28% | 11.83% | 26.25% | 78.93% |
 Boston Scientific Corp. | 2.53% | 38.01% | 34.98% | 63.21% | 86.81% |
 Edwards Lifesciences Corp. | -5.81% | 24.49% | -1.17% | -8.62% | 48.12% |
 Abbott Laboratories | -2.2% | 13.48% | -2.16% | -12.23% | 37.74% |
 Medtronic Plc | -3.44% | 13.85% | -10.38% | -37.53% | -7.46% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Zomedica Corp | NA | NA | NA | -0.01 | -0.14 | -0.07 | NA | 0.25 |
Stryker Corporation | 39.67 | 39.67 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.57 | 63.57 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 38.15 | 38.15 | 5.19 | 2.75 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.36 | 33.36 | 5.99 | 4.61 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.58 | 25.58 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Zomedica Corp | Buy | $127.5M | -63.63% | NA | -137.1% |
Stryker Corporation | Buy | $124.7B | 78.93% | 39.67 | 15.44% |
Boston Scientific Corp. | Buy | $100.0B | 86.81% | 63.57 | 11.18% |
Edwards Lifesciences Corp. | Buy | $52.8B | 48.12% | 38.15 | 23.36% |
Abbott Laboratories | Buy | $185.8B | 37.74% | 33.36 | 13.96% |
Medtronic Plc | Buy | $107.0B | -7.46% | 25.58 | 13.0% |
Corporate Announcements
Zomedica Corp Earnings
Zomedica Corp’s price-to-earnings ratio stands at None
Read More
Company Information
zomedica (nyse american:zom) (tsx-v:zom) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. with a team that includes clinical veterinary professionals, it is zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.
Organization | Zomedica Corp |
Employees | 144 |
CEO | Mr. Larry C. Heaton II |
Industry | Health Technology |
